Open AccessDrug-induced Fatty Liver Disease: Pathogenesis and Treatment
Author(s) -
Tea Omanović Kolarić,
Vjera Ninčević,
Lucija Kuna,
Kristina Duspara,
Kristina Bojanić,
Sonja Vukadin,
Nikola Raguž-Lučić,
George Y. Wu,
Martina Smolić
Publication year - 2021
Publication title -
journal of clinical and translational hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.042
H-Index - 29
eISSN - 2310-8819
pISSN - 2225-0719
DOI - 10.14218/jcth.2020.00091
Subject(s) - medicine , polypharmacy , fatty liver , disease , drug , epidemiology , metabolic syndrome , incidence (geometry) , pathogenesis , obesity , intensive care medicine , liver injury , liver disease , bioinformatics , pharmacology , physics , optics , biology
Metabolic dysfunction-associated fatty liver disease (commonly known as MAFLD) impacts global health in epidemic proportions, and the resulting morbidity, mortality and economic burden is enormous. While much attention has been given to metabolic syndrome and obesity as offending factors, a growing incidence of polypharmacy, especially in the elderly, has greatly increased the risk of drug-induced liver injury (DILI) in general, and drug-induced fatty liver disease (DIFLD) in particular. This review focuses on the contribution of DIFLD to DILI in terms of epidemiology, pathophysiology, the most common drugs associated with DIFLD, and treatment strategies.